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pital admissions between the 2 groups. Total mean medical costs
were signiﬁcantly higher in MLD patients ($35,173) compared
to HCC patients ($22,465, p < 0.001). Inpatient costs con-
tributed 61% ($13,687) to the total cost in HCC patients com-
pared to 45% ($14,349, p < 0.05) in MLD patients. Conversely,
46% ($16,006) of the total cost in MLD patients was due to
physician costs (including chemotherapy), compared to only
27% ($6115, p < 0.001) in HCC patients. CONCLUSIONS:
Among Medicare patients newly diagnosed with HCC or MLD,
signiﬁcantly higher 1-year health resource use and medical costs
were found in MLD patients. The difference in overall costs was
due primarily to higher physician (including ofﬁce) costs among
MLD patients. These ﬁndings provide important new data for
evaluating the economic impact of treating HCC and MLD
patients in the Medicare population.
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OBJECTIVES: To investigate the health care utilization and
direct medical costs associated with treating early and late stage
oropharyngeal cancer within the ﬁrst year following diagnosis.
METHODS: A retrospective database analysis was conducted
using California Medicaid claims data merged with mortality
data for the years 1995 to 2003. Patients diagnosed with oropha-
ryngeal cancer were identiﬁed using a 6-month wash-out period
and were either continuously eligible for 12 months following
diagnosis or had a recorded death within that year. Utilization
of health care resources was assessed and direct Medicaid pay-
ments were calculated. Subgroup analysis was preformed on
patients with early and late stage disease as deﬁned by their
cancer treatment. Using treatment to deﬁne tumor stage was in
accordance to Modi’s 2005 review of the standard of care for
treatment of squamous cell carcinoma of the head and neck.
Regression was used to determine signiﬁcant predictors of total
one year Log cost of care in this population. RESULTS: We iden-
tiﬁed 322 who were diagnosed and treated for oropharyngeal
cancer. The median one year cost of care for these Medicaid
patients was $26,763. Total health care spending was 38.03%
higher for patients who received early stage treatment and died
within the year (p = 0.0164), 53.54% higher for patients who
received late-stage treatment and survived the year (p = 0.0036),
and 85.29% higher for patients who had late stage treatment
and died within the year (p = 0.0033) compared with patients
who received early stage treatment and survived. Comorbidities
and their interaction with age were also signiﬁcant (p < 0.01) in
predicting Log costs. CONCLUSIONS: Oropharyngeal cancer is
a signiﬁcant cost from the insurer’s perspective. In addition to
improved prognosis and quality of life, early diagnosis may
reduce the cost of care to the insurer and therefore efforts should
be made to diagnose oral tumors at an earlier stage.
PCN18
CLINICAL AND ECONOMIC OUTCOMES OF INITIAL ACUTE
MYELOBLASTIC LEUKEMIA (AML) HOSPITALIZATION 
IN THE ELDERLY
Nuyts G1, Janagap C1, Zilberberg M2, Piech CT2
1Johnson and Johnson, Raritan, NJ, USA, 2Ortho Biotech Clinical
Affairs, LLC, Bridgewater, NJ, USA
OBJECTIVES: AML in the elderly is characterized by high short-
term mortality and economic burden, with hospitalizations as
the main driver. We examined clinical and economic outcomes
of the initial hospitalization in an elderly cohort with newly-
diagnosed AML. METHODS: An analysis of the 2002 Premier
Perspective inpatient database was performed in patients >65
years with a new diagnosis of AML. RESULTS: A total of 509
(46% female) patients accounting for 803 hospital admissions,
met the inclusion criteria. There was an equal proportion of
patients in the groups aged 65–74 and >75. Of the 183 (36%)
patients receiving chemotherapy (CT) on ﬁrst admission, 41%
received standard induction (SI), 31% non-SI and 27% hydrox-
yurea (H). Among CT group, more SI patients were younger than
non-SI patients (73% and 51% 65–74yrs, respectively), while
fewer non-CT and H patients were younger (39% and 32%, 65–
75yrs, respectively). CT patients were less likely to have comor-
bidities (8%) compared to non-CT (17%). Sixty-three percent of
all hospital deaths occurred during the ﬁrst hospitalization with
the majority occurring within the ﬁrst two weeks. Overall hos-
pital death rate during the ﬁrst hospitalization was 29%, but
higher in SI (39%) and non-SI (40%). Longer hospital stay in SI
and non-SI patients, 30 and 21 days, respectively, was also
observed, compared to 12 days overall. Mean (SD) costs of ﬁrst
hospitalization was $36,866 ($33,045) and $8936($10,340) for
CT and non-CT, respectively but comparable on a per day basis.
CONCLUSIONS: AML remains devastating and costly. Hospi-
tal mortality is high during the initial hospitalization, and a sub-
stantial proportion of deaths in this period occurs within the ﬁrst
two weeks.
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OBJECTIVES: With availability of several colorectal cancer
screening tools, the cost-effectiveness of population-based
screening programmes is of interest. The goal of this study was
to estimate the per-procedure cost of conventional colonoscopy
(COL) and ﬂexible sigmoidoscopy (SIG) in an outpatient
endoscopy clinic. METHODS: An activity based costing
approach was carried out using time-and-motion techniques on
104 COL and 48 SIG procedures performed in St. Paul’s Hos-
pital (SPH) between July and October 2004. Observation began
with patient registration in the clinic and ended with patient dis-
charge. Direct costs, including nursing and physician time, sup-
plies and medications, were estimated. Indirect costs included
physician and pathology fees, scope repair and cleaning
expenses. Hospital overhead costs were determined through SPH
ﬁnance department. Total cost was calculated as the sum of
direct, indirect and overhead costs. Student’s t-tests were per-
formed to determine any signiﬁcant differences (P < 0.10) of
mean total cost between groups derived from baseline variables.
Linear regression analysis of cost was also conducted. All costs
are reported in 2004 Canadian dollars. RESULTS: Mean age of
patients was 56 (22; 88) years for COL and 51 (17; 90) years
for SIG. Mean total time was 189 (106; 317) minutes for COL
and 53 (14; 111) minutes for SIG. Mean procedure time for COL
and SIG was 34 (18; 61) minutes and 14 (7; 35) minutes, respec-
tively. Total cost was $522 ($360; $679) for COL and $176
($105; $287) for SIG. Physician and pathology fees accounted
for 61% of total cost for COL and 58% for FSIG. Number of
biopsies and total time have signiﬁcant predictive power on total
cost for both procedures. Sex and number of polypectomies are
